More recently, immunotherapy, such as use of the monoclonal antibodies, pembrolizumab which inhibits programmed cell death 1 (PD-1) and atezolizumab, an inhibitor of the programmed cell death ligand 1 (PD-L1) that releases the suppression of the PD-1/PD-L1–mediated immune response in patients with triple negative breast cancer, has shown promise [69]. The gene discussed is CD274; the disease is triple-negative breast carcinoma.